Q4 Earnings Forecast for Humacyte Issued By HC Wainwright

Humacyte, Inc. (NASDAQ:HUMA) – HC Wainwright issued their Q4 2027 earnings estimates for shares of Humacyte in a research report issued to clients and investors on Thursday, May 14th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings per share of ($0.05) for the quarter. The consensus estimate for Humacyte’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Humacyte’s FY2029 earnings at $0.06 EPS and FY2030 earnings at $0.34 EPS.

Humacyte (NASDAQ:HUMA) last released its earnings results on Wednesday, May 13th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. The company had revenue of $0.50 million for the quarter, compared to analysts’ expectations of $1.46 million. Humacyte had a negative net margin of 4,836.06% and a negative return on equity of 2,914.18%.

Other equities analysts also recently issued reports about the stock. BTIG Research dropped their target price on shares of Humacyte from $3.00 to $2.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Benchmark dropped their price objective on shares of Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, January 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of Humacyte in a research report on Friday, April 10th. Wall Street Zen raised shares of Humacyte from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of Humacyte in a report on Tuesday, April 28th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $7.57.

Humacyte Stock Down 8.1%

Shares of NASDAQ HUMA opened at $0.83 on Monday. The firm’s 50-day moving average price is $0.84 and its 200-day moving average price is $1.05. The company has a current ratio of 3.93, a quick ratio of 3.32 and a debt-to-equity ratio of 5.46. The stock has a market capitalization of $183.23 million, a price-to-earnings ratio of -1.45 and a beta of 2.31. Humacyte has a 12-month low of $0.55 and a 12-month high of $2.93.

Institutional Investors Weigh In On Humacyte

Several large investors have recently added to or reduced their stakes in HUMA. Marshall Wace LLP grew its holdings in Humacyte by 5,308.2% during the 2nd quarter. Marshall Wace LLP now owns 2,639,194 shares of the company’s stock worth $5,516,000 after acquiring an additional 2,590,394 shares in the last quarter. Millennium Management LLC grew its stake in Humacyte by 129.5% in the 4th quarter. Millennium Management LLC now owns 2,631,990 shares of the company’s stock valued at $2,528,000 after acquiring an additional 1,485,152 shares during the last quarter. UBS Group AG boosted its stake in shares of Humacyte by 48.8% during the 4th quarter. UBS Group AG now owns 2,978,610 shares of the company’s stock worth $2,862,000 after purchasing an additional 976,275 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Humacyte by 33.4% during the 2nd quarter. Geode Capital Management LLC now owns 2,948,508 shares of the company’s stock worth $6,163,000 after purchasing an additional 738,142 shares during the last quarter. Finally, Barclays PLC boosted its position in shares of Humacyte by 298.7% in the fourth quarter. Barclays PLC now owns 729,469 shares of the company’s stock worth $701,000 after acquiring an additional 546,491 shares during the last quarter. 44.71% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Humacyte

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: TD Cowen raised its price target on Humacyte to $1.50 from $1.00, a sign that the firm sees more upside potential despite the company still being in early-stage commercialization. Why Humacyte, Inc. (HUMA) Price Target Was Raised Despite Early-Stage Commercialization
• Positive Sentiment: Analyst revisions from HC Wainwright included better longer-term earnings estimates than before for some periods, which can support sentiment around Humacyte’s future operating leverage. Humacyte analyst estimates
• Neutral Sentiment: HC Wainwright reiterated a series of EPS forecasts showing continued losses through 2026-2028, indicating the company is still expected to burn cash while it scales. Humacyte analyst estimates
• Negative Sentiment: The same analyst updates also trimmed FY2026, FY2027, and FY2028 EPS estimates, underscoring ongoing concerns about earnings pressure and a slow path to profitability. Humacyte analyst estimates
• Negative Sentiment: Humacyte’s recent quarterly results showed minimal revenue and losses that were still significant, which helps explain why the stock remains under pressure despite analyst optimism. Humacyte earnings results

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.